Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade · PMID 42321916
View analysis →A grade · PMID 42372741
View analysis →A grade · PMID 42382416
View analysis →A grade · PMID 42150584
View analysis →This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 82.2/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 66.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 82.1/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 33.0; sample size: 70.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 82.1/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 62.8; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 82.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 60.2; sample size: 30.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 82.0/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 30.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 82.0/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 60.0; sample size: 30.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.7/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 71.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.6/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 73.2; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.6/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 48.0; sample size: 20.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.5/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 57.7; sample size: 50.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.5/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 60.0; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.5/100. Study design: 95.0; human relevance: 75.0; therapeutic relevance: 59.8; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.4/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 52.2; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.4/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 52.0; sample size: 40.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.3/100. Study design: 70.0; human relevance: 90.0; therapeutic relevance: 83.8; sample size: 70.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.1/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 43.2; sample size: 40.0; recency: 100.0; abstract quality: 85.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.1/100. Study design: 90.0; human relevance: 100.0; therapeutic relevance: 45.7; sample size: 50.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.1/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 35.5; sample size: 40.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.0/100. Study design: 100.0; human relevance: 75.0; therapeutic relevance: 50.2; sample size: 60.0; recency: 100.0; abstract quality: 100.0.
This pediatric cancer paper has not been AI summarized yet.
Deterministic evidence score: 81.0/100. Study design: 100.0; human relevance: 100.0; therapeutic relevance: 20.0; sample size: 70.0; recency: 100.0; abstract quality: 100.0.
